Patent intelligence · US
US 9849133
Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
Patent details — US 9849133
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 26, 2017
- Expiration
- Dec 21, 2037
- Applicant
- Eton Pharmaceuticals, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K31/417, A61K31/472, A61K31/522
Quick answer
US 9849133 (Pharmaceutical formulations of xanthine or xanthine derivatives, and their use) is held by Eton Pharmaceuticals, Inc.. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Eton Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/417, A61K31/472, A61K31/522, A61K31/5575, A61K38/4886
More from Eton Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419831
Hydrocortisone oral liquid formulations
granted -
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
granted -
US 12357582
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12329816
Immunotherapy with metabolic enzyme expression
granted -
US 12209256
System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction
granted -
US 12195768
System and method for modulating stress granule assembly
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted
Frequently asked questions
What is US patent 9849133?
US 9849133 (Pharmaceutical formulations of xanthine or xanthine derivatives, and their use) is held by Eton Pharmaceuticals, Inc.. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9849133?
Eton Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.
When does US 9849133 expire?
Our index shows an expiration date of Dec 21, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.